La maladie de Parkinson en France (serveur d'exploration) - Exploration (Accueil)

Index « Keywords » - entrée « Antiparkinson Agents (adverse effects) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Antiparkinson Agents (administration & dosage) < Antiparkinson Agents (adverse effects) < Antiparkinson Agents (chemistry)  Facettes :

List of bibliographic references indexed by Antiparkinson Agents (adverse effects)

Number of relevant bibliographic references: 132.
[40-60] [0 - 20][0 - 50][60-80]
Ident.Authors (with country if any)Title
001723 (2011) O. Rascol [France]Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release
001998 (2010) Santiago Perez Lloret [France] ; Olivier RascolPramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease.
001C04 (2010) Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease
001C10 (2010) David Devos [France] ; L. Defebvre [France] ; R. Bordet [France]Dopaminergic and non‐dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease
001E72 (2009) C. Ardouin [France] ; I. Chéreau ; P-M Llorca ; E. Lhommée ; F. Durif ; P. Pollak ; P. Krack[Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease].
001E89 (2009) Olivier Rascol [France] ; Santiago Perez-LloretRotigotine transdermal delivery for the treatment of Parkinson's disease.
001E92 (2009) Clemence Simonin [France] ; M. Tir ; D. Devos ; A. Kreisler ; K. Dujardin ; J. Salleron ; A. Delval ; S. Blond ; L. Defebvre ; A. Destée ; P. KrystkowiakReduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon.
001F21 (2009) Alain Destée [France] ; Karin Rérat ; Isabelle BourdeixIs there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
001F36 (2009) Philippe Damier [France]Drug-induced dyskinesias.
002048 (2009) David Devos [France]Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease
002207 (2009) Joëlle Micallef [France] ; Marc Rey [France] ; Alexandre Eusebio [France] ; Christine Audebert [France] ; Frank Rouby [France] ; Elisabeth Jouve [France] ; Sophie Tardieu [France] ; Oliver Blin [France]Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects
002214 (2009) E. Lohmann [France] ; S. Thobois [France] ; S. Lesage [France] ; E. Broussolle [France] ; S. Tezenas Du Montcel [France] ; M.-J. Ribeiro [France] ; P. Remy [France] ; A. Pelissolo [France] ; B. Dubois [France] ; L. Mallet [France] ; P. Pollak [France] ; Yves Agid [France] ; A. Brice [France]A multidisciplinary study of patients with early-onset PD with and without parkin mutations
002292 (2008) Gilles Fénelon [France]Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms.
002295 (2008) Agnès Nadjar [France] ; Charles R. Gerfen [États-Unis] ; Erwan Bezard [France]Priming for L-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease?
002545 (2008) Dominique Guehl [France] ; Pierre Burbaud [France] ; Christian Lorenzi [France] ; Christophe Ramos [France] ; Bernard Bioulac [France] ; Catherine Semal [France] ; Laurent Demany [France]Auditory temporal processing in Parkinson's disease
002824 (2007) Jean-Christophe Corvol [France] ; Jean-Baptiste Anzouan-Kacou [France] ; Elodie Fauveau [France] ; Anne-Marie Bonnet [France] ; Bénédicte Lebrun-Vignes [France] ; Camille Girault [France] ; Yves Agid [France] ; Philippe Lechat [France] ; Richard Isnard [France] ; Lucette Lacomblez [France]Heart Valve Regurgitation, Pergolide Use, and Parkinson Disease : An Observational Study and Meta-analysis
002A02 (2006) Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
002A92 (2006) Jean-Pierre Wolf [France] ; Malika Bouhaddi [France] ; Francis Louisy [France] ; Andrei Mikehiev [France] ; Laurent Mourot [France] ; Sylvie Cappelle [France] ; Fabrice Vuillier [France] ; Pierre Andre [France] ; Lucien Rumbach [France] ; Jacques Regnard [France]Side-effects of l-dopa on venous tone in Parkinson's disease : a leg-weighing assessment
002B71 (2005) C. Guigoni [France] ; I. Aubert ; Q. Li ; V V Gurevich ; J L Benovic ; S. Ferry ; U. Mach ; H. Stark ; L. Leriche ; K. H Kansson ; Bernard H. Bioulac ; Christian E. Gross ; Pierre Sokoloff ; Gilberto Fisone ; E V Gurevich ; Bertrand Bloch ; Erwan BezardPathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
002B77 (2005) Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
002B79 (2005) Isabelle Arnulf [France]Excessive daytime sleepiness in parkinsonism.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Antiparkinson Agents (adverse effects)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Antiparkinson Agents (adverse effects)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Antiparkinson Agents (adverse effects)
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024